2 Views on Vertex Pharmaceuticals Stock: Short Term vs. Long Term
There's a lot for investors to really like about Vertex Pharmaceuticals (NASDAQ: VRTX). The company reached profitability earlier this year. It has reported a string of positive clinical results for its cystic fibrosis drugs. And, oh yes, the stock has more than doubled so far in 2017.
Chief Commercial Officer Stuart Arbuckle answered questions at the Morgan Stanley healthcare conference on Monday, and his comments highlighted the two totally different ways investors should be looking at Vertex. Here are the fast-growing biotech's short-term and long-term challenges and opportunities.
Image source: Getty Images.
Source: Fool.com
Vertex Pharmaceuticals Inc. Aktie
430,90 €
-0,47 %
Die Community sieht Vertex Pharmaceuticals Inc. positiv: Viel mehr Buy- als Sell-Einschätzungen.
Ein leicht positives Kursziel von 459 € für Vertex Pharmaceuticals Inc. gegenüber dem aktuellen Kurs von 430.9 € wird gesehen.
